Literature DB >> 4027864

Patterns of relapse in locally advanced head and neck cancer patients who achieved complete remission after combined modality therapy.

W K Hong, R H Bromer, D A Amato, S Shapshay, M Vincent, C Vaughan, B Willett, A Katz, J Welch, S Fofonoff.   

Abstract

Relapse patterns in patients with locally advanced head and neck cancer who achieved complete remission were evaluated. After combined modality therapy with induction chemotherapy followed by surgery and/or radiotherapy, 71 of 103 patients were clinically free of disease. The 5-year recurrence rate was estimated at 51%, with a 39% local and 26% distant failure rate by 5 years. The factors significantly affecting the relapse patterns were: the site of the primary tumor (those with oral cavity lesions were more likely to fail locally, whereas hypopharynx patients had a higher risk of distant metastases); the type of definitive local treatment (those patients who received surgery and radiotherapy were at lower risk of pure local failure); TN Stage (patients with T4N3 or T3N3 tumor were at higher risk of both local and distant failure); and time to response and presence of oropharyngeal lesions (patients who had a longer period from diagnosis to final complete response [CR] and patients with oropharyngeal primaries were at higher risk for simultaneous local and distant failure). Type of chemotherapy, patient age, tumor differentiation, and response to induction chemotherapy did not significantly influence the patterns of relapse. A combined modality approach with induction chemotherapy, surgery, and/or radiotherapy does not seem to reduce the incidence of distant metastases significantly.

Entities:  

Mesh:

Year:  1985        PMID: 4027864     DOI: 10.1002/1097-0142(19850915)56:6<1242::aid-cncr2820560603>3.0.co;2-z

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  15 in total

Review 1.  Radiation enhancement of metastasis: a review.

Authors:  C F von Essen
Journal:  Clin Exp Metastasis       Date:  1991 Mar-Apr       Impact factor: 5.150

2.  Endostatin inhibits lymph node metastasis by a down-regulation of the vascular endothelial growth factor C expression in tumor cells.

Authors:  Shunsuke Fukumoto; Masayo Morifuji; Yoshinori Katakura; Masamichi Ohishi; Seiji Nakamura
Journal:  Clin Exp Metastasis       Date:  2005       Impact factor: 5.150

Review 3.  Induction Chemotherapy in Low-Risk HPV+ Oropharyngeal Cancer.

Authors:  James M Dolezal; Ari J Rosenberg
Journal:  Curr Treat Options Oncol       Date:  2022-02-16

Review 4.  Optimizing Treatment De-Escalation in Head and Neck Cancer: Current and Future Perspectives.

Authors:  Ari J Rosenberg; Everett E Vokes
Journal:  Oncologist       Date:  2020-09-21

5.  A nomogram to predict loco-regional control after re-irradiation for head and neck cancer.

Authors:  Nadeem Riaz; Julian C Hong; Eric J Sherman; Luc Morris; Matthew Fury; Ian Ganly; Tony J C Wang; Weji Shi; Suzanne L Wolden; Andrew Jackson; Richard J Wong; Zhigang Zhang; Shyam D Rao; Nancy Y Lee
Journal:  Radiother Oncol       Date:  2014-06-30       Impact factor: 6.280

Review 6.  Locally advanced head and neck cancer.

Authors:  M S Kies; C L Bennett; E E Vokes
Journal:  Curr Treat Options Oncol       Date:  2001-02

Review 7.  The role of RNA processing and regulation in metastatic dormancy.

Authors:  Kimberly A Parker; Nathaniel J Robinson; William P Schiemann
Journal:  Semin Cancer Biol       Date:  2021-03-26       Impact factor: 15.707

8.  Long-term outcome and toxicity of hypofractionated stereotactic body radiotherapy as a boost treatment for head and neck cancer: the importance of boost volume assessment.

Authors:  Dong Soo Lee; Yeon Sil Kim; Jae Seok Cheon; Jin Ho Song; Seok Hyun Son; Ji Sun Jang; Young Nam Kang; Jing Hyoung Kang; So Lyoung Jung; Ie Ryung Yoo; Hong Seok Jang
Journal:  Radiat Oncol       Date:  2012-06-12       Impact factor: 3.481

9.  Quality of Life Analysis of HPV-Positive Oropharyngeal Cancer Patients in a Randomized Trial of Reduced-Dose Versus Standard Chemoradiotherapy: 5-Year Follow-Up.

Authors:  Mai Takahashi; Michael Hwang; Krysztof Misiukiewicz; Vishal Gupta; Brett A Miles; Richard Bakst; Eric Genden; Isaiah Selkridge; John Botzler; Vruti Virani; Erin Moshier; Marcelo R Bonomi; Marshall R Posner
Journal:  Front Oncol       Date:  2022-04-08       Impact factor: 5.738

10.  Persistently elevated soluble MHC class I polypeptide-related sequence A and transforming growth factor-β1 levels are poor prognostic factors in head and neck squamous cell carcinoma after definitive chemoradiotherapy.

Authors:  Jenny Ling-Yu Chen; Chien-Chung Chang; Yu-Sen Huang; Hung-Yang Kuo; Tzu-Yu Chen; Chun-Wei Wang; Sung-Hsin Kuo; Yu-Li Lin
Journal:  PLoS One       Date:  2018-08-10       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.